Details

Autor(en) / Beteiligte

• Saxena, Amit
• Ginzler, Ellen M.
• Gibson, Keisha
• Satirapoj, Bancha
• Santillán, Adolfina Elizabeth Zuta
• Levchenko, Olena
• Navarra, Sandra
• Atsumi, Tatsuya
• Yasuda, Shinsuke
• Chavez‐Perez, Nilmo Noel
• Arriens, Cristina
• Parikh, Samir V.
• Caster, Dawn J.
• Birardi, Vanessa
• Randhawa, Simrat
• Lisk, Laura
• Huizinga, Robert B.
• Teng, Y. K. Onno

Titel

Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial

Ist Teil von

• Arthritis & rheumatology (Hoboken, N.J.), 2024-01, Vol.76 (1), p.59-67

Ort / Verlag

Boston, USA: Wiley Periodicals, Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one‐year AURORA 1 study. Methods Enrolled patients continued their double‐blinded treatment of voclosporin or placebo randomly assigned in AURORA 1, in combination with mycophenolate mofetil and low‐dose glucocorticoids. The primary objective was safety assessed with adverse events (AEs) and biochemical and hematological assessments. Efficacy was measured by renal response. Results A total of 216 patients enrolled in AURORA 2. Treatment was well tolerated with 86.1% completing the study and no unexpected safety signals. AEs occurred in 86% and 80% of patients in the voclosporin and control groups, respectively, with an AE profile similar to that seen in AURORA 1, albeit with reduced frequency. Investigator reported AEs of both glomerular filtration rate (GFR) decrease and hypertension occurred more frequently in the voclosporin than the control group (10.3% vs 5.0%, and 8.6% vs 7.0%, respectively). Mean corrected estimated GFR (eGFR) was within the normal range and stable in both treatment groups. eGFR slope over the two‐year period was −0.2 mL/min/1.73 m2 (95% confidence interval [CI] −3.0 to 2.7) in the voclosporin group and −5.4 mL/min/1.73 m2 (95% CI −8.4 to −2.3) in the control group. Improved proteinuria persisted across three years of treatment, leading to more frequent complete renal responses in patients treated with voclosporin (50.9% vs 39.0%; odds ratio 1.74; 95% CI 1.00–3.03). Conclusion Data demonstrate the safety and efficacy of long‐term voclosporin treatment over three years of follow‐up in patients with LN.